Harnessing the power
Pure Biologics’ therapeutic portfolio includes new immunooncology therapies and non-systemic treatment of kidney diseases. In these innovative projects we use antibody and aptamer technologies to develop molecules with therapeutic potential.
Investors & media
Pure Biologics is the first entity in Poland to focus on development of completely new, not generic or biosimilar, biological drugs based on antibodies and therapeutic aptamers. This is a challenge that is currently a leading trend in the global pharmaceutical industry.